Sign Out
Hypersensitivity to epirubicin hydrochloride or to any of the excipients, other anthracyclines or anthracenediones.
Lactation.
Intravenous use: Patients with marked or persistent myelosuppression induced by previous treatment with either other anti-neoplastic agents or radiotherapy.
Patients with severe hepatic impairment.
Severe myocardial insufficiency.
Recent myocardial infarction.
Severe arrhythmias.
Previous treatments with maximum cumulative doses of epirubicin and/or other anthracyclines such as doxorubicin or daunorubicin and anthracenediones.
Or previous history of cardiac impairment (including 4th degree muscular heart failure, acute heart attack and previous heart attack which led to 3rd and 4th degree muscular heart failure, acute inflammatory heart diseases, severe arrhythmia, myocardiopathy, recent myocardial infarction) patients with acute systemic infections.
Patients with unstable angina pectoris.
Myocardiopathy.
Intravesical use: Urinary tract infections.
Inflammation of the bladder.
Haematuria.
Invasive tumours penetrating the bladder.
Catheterisation problems.
Large volume of residual urine.
Contracted bladder.
Continue with Google